In prostate cancer, lineage plasticity results in extensive reprogramming of the epigenetic landscape, including changes in the cistrome of the master transcription factor FOXA1 (23) or switch to other master transcription factors, such as loss of AR and gain of ASCL1 or NEUROD1 in NEPC (24, 25). Here, ASCL1 is linked to prostate cancer.